Malin appoints new chief medical officer
Irish-based global life-sciences investment company Malin has appointed Dr Andrew von Eschenbach as chief medical adviser.
Mr von Eschenbach - who previously served as an advisory partner to the company - will work with the management team and the company's therapeutic-assets team.
Initially his focus will be on oncology and immuno-oncology-related companies, including Poseida and Immunocore.
The American native is the president of Samaritan Health Initiatives, and serves as an adjunct professor at Houston's University of Texas MD Anderson Cancer Center.
He is also a member of the Prostate Cancer Foundation board of directors and a senior fellow at the Milken Institute, a non-profit think tank.
He previously served as the commissioner of the Food and Drug Administration from 2006 to 2009, and was the director of the National Cancer Institute at the National Institute of Health for four years.
"We are delighted to welcome Andrew to this broader role within the Malin team," said Malin CEO Adrian Howd.
"His extensive clinical, executive and regulatory knowledge and experience will greatly benefit our portfolio companies."
In April this year Malin announced plans to raise €30m via a private placing "in response to market demand", but did not say what it would use the funds for.
Malin raised €330m when it floated on the Irish Stock Exchange in 2015. Its backers included the Ireland Strategic Investment Fund.
In 2015 it raised a further €40m from the market, and it has also secured a €70m, seven-year facility from the European Investment Bank.